Company registration number 01737587 (England and Wales)
NORMEC LATIS SCIENTIFIC LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
NORMEC LATIS SCIENTIFIC LIMITED
COMPANY INFORMATION
Directors
Ms B D Schuurs
Ms M H van Schaik
K Maynard
(Appointed 10 September 2025)
Company number
01737587
Registered office
Unit C1 Acorn Industrial Park
Crayford Road
Crayford
Dartford
United Kingdom
DA1 4AL
Auditor
Azets Audit Services
7 - 8 Britannia Business Park
Comet Way
Southend-On-Sea
Essex
United Kingdom
SS2 6GE
NORMEC LATIS SCIENTIFIC LIMITED
CONTENTS
Page
Strategic report
1 - 2
Directors' report
3 - 4
Independent auditor's report
5 - 7
Profit and loss account
8
Balance sheet
9
Statement of changes in equity
10
Notes to the financial statements
11 - 26
NORMEC LATIS SCIENTIFIC LIMITED
STRATEGIC REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025
- 1 -

The directors present the strategic report for the year ended 31 December 2025.

Principal activities

The principal activity of the company during the year was that of providing high quality science, technology and consultancy services to water quality within building and recreational water facilities.

Review of the business

Normec Latis Scientific Limited is a market leading provider of laboratory services. We are part of a multi national laboratory services network, committed to the environment and prepared to globally serve their markets and exceed customer expectations.

 

Normec Latis Scientific offer a comprehensive range of accredited and tailored microbiological laboratory services, with expert consultancy for many aspects of water, air and environmental microbiology. Our focus is to deliver scientifically and technically valid results, independently assessed by the UK National Accreditation Body (UKAS). All methods are continuously updated to comply with current UK and European legislation, guidance and recommendations.

 

Normec Latis Scientific are experts in the field of analytical chemistry and microbiology. We can tailor analysis to the client’s specific requirements or provide bespoke project work. Our team’s multi disciplinary background brings experience of a wide range of tests and procedures, and our state-of-the-art laboratories offer an extensive range of analysis on many different matrices.

Principal risks and uncertainties

The principal risks and uncertainties facing the company are broadly grouped as competitive and financial instrument risks. The company's activities expose it to a number of financial instrument risks including credit risk, interest rate risk, cash flow risk, foreign currency risk and liquidity risk.

 

The directors continually review and evaluate the risks that the company is facing. Currency fluctuations, trading arrangements, employment issues and other risks that become apparent over time will be monitored by management and mitigation put in place where possible.

 

The main risks associated with the company's financial assets and liabilities are set out below:

 

Inflationary impact

The company continues to manage the impact of inflationary costs, both in costs from its supply chain and also to price its services accordingly. The situation is very fluid with regular reviews required to ensure the business remains competitive.

 

Competitive risks

The company will continue to exploit existing and new market opportunities in the laboratory, medical and industrial sectors. Research and development activities will be undertaken to both strengthen its ability to service existing and new customers and also to update the product range as considered appropriate.

 

Financial instrument risks

The management team conducts an annual risk assessment of the business and manages the risks identified to proactively prevent any material and adverse risk to the company's future operating profits or financial position.

The objectives aim to limit undue counterparty exposure, ensure sufficient working capital exists and monitor the management of risk.

 

 

NORMEC LATIS SCIENTIFIC LIMITED
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 2 -

Credit risks

The company monitors the exposure to credit risk on an ongoing basis and credit evaluations are performed on customers requiring credit. Credit risks are also minimised by limiting the company’s business partners with high credit worthiness.

 

Interest rate risks

The company's exposure to risk of changes in interest rates may arise from the company's loans from its parent undertaking. Intercompany interest rates are lower than the company would achieve through external borrowing facilities and this mitigates the risk to a reasonable extent.

 

Foreign currency risk

The company's principal transactions in foreign currency are in respect of intercompany recharges and loa arrangements in Euros. The gain/(loss) on exchange is derived from revaluing the outstanding creditors at current exchange rates. No hedging activity is undertaken locally to mitigate the exchange risk.

 

Liquidity risks

Liquidity risk is the risk of non-availability of funding for the company's business activities. This risk is managed by focusing on working capital flows, and access to the group intercompany loan facility.

 

Cash flow risks

The company has received assurances from Greyhound Dutch Bidco B.V., the ultimate parent of the company, that it shall continue to provide full working capital support for the company until 31 August 2027.

 

The company has no other significant risks or uncertainties other than those that arise from being a part of the Greyhound Dutch Bidco B.V. group which are dealt with in the Strategic Report presented in the Consolidated Financial Statements 2025 of Greyhound Dutch Bidco B.V., copies of which are available to public as mentioned in note 23 of the financial statements.

Key performance indicators

Revenue increased by £1,807,329 from 2024 to 2025 representing an increase of 19.37% (2024: 15.92% increase). Gross margin decreased from 44.57% in 2024 to 42.95% in 2025 which relates to the impact of inflationary pressures on price and increase in laboratory staff to drive revenue growth.

Other performance indicators

During the year the company maintained it's excellent environmental standards by recording no pollution incidents or environmental complaints during the year (2024: none).

 

This report was approved by the board on 31 July 2026 and signed on its behalf.

On behalf of the board

K Maynard
Director
24 September 2026
NORMEC LATIS SCIENTIFIC LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025
- 3 -

The directors present their annual report and financial statements for the year ended 31 December 2025.

Results and dividends

The results for the year are set out on page 8.

No ordinary dividends were paid. The directors do not recommend payment of a final dividend.

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

Ms B D Schuurs
Ms M H van Schaik
Mr R M Wolff
(Resigned 1 February 2026)
K Bridgewood
(Resigned 16 September 2025)
K Maynard
(Appointed 10 September 2025)
Supplier payment policy

The company's current policy concerning the payment of trade creditors is to follow the CBI's Prompt Payers Code (copies are available from the CBI, Centre Point, 103 New Oxford Street, London WC1A 1DU).

 

The company's current policy concerning the payment of trade creditors is to:

 

Trade creditors of the company at the year end were equivalent to 88 day's purchases, based on the average daily amount invoiced by suppliers during the year.

Statement of directors' responsibilities

The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.

 

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with International Financial Reporting Standards (IFRSs) as adopted by the United Kingdom. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, International Accounting Standard 1 requires that directors:

 

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

NORMEC LATIS SCIENTIFIC LIMITED
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 4 -
Statement of disclosure to auditor

So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the company’s auditor is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the company’s auditor is aware of that information.

Medium-sized companies exemption

This report has been prepared in accordance with the provisions applicable to companies entitled to the medium-sized companies exemption.

On behalf of the board
K Maynard
Director
24 September 2026
NORMEC LATIS SCIENTIFIC LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF NORMEC LATIS SCIENTIFIC LIMITED
- 5 -
Opinion

We have audited the financial statements of Normec Latis Scientific Limited (the 'company') for the year ended 31 December 2025 which comprise the profit and loss account, the balance sheet, the statement of changes in equity and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 101 Reduced Disclosure Framework (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

 

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

 

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

NORMEC LATIS SCIENTIFIC LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF NORMEC LATIS SCIENTIFIC LIMITED (CONTINUED)
- 6 -
Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report.

 

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities is available on the Financial Reporting Council's website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

NORMEC LATIS SCIENTIFIC LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF NORMEC LATIS SCIENTIFIC LIMITED (CONTINUED)
- 7 -

Extent to which the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above and on the Financial Reporting Council’s website, to detect material misstatements in respect of irregularities, including fraud.

 

We obtain and update our understanding of the entity, its activities, its control environment, and likely future developments, including in relation to the legal and regulatory framework applicable and how the entity is complying with that framework.  Based on this understanding, we identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion.  This includes consideration of the risk of acts by the entity that were contrary to applicable laws and regulations, including fraud.

 

In response to the risk of irregularities and non-compliance with laws and regulations, including fraud, we designed procedures which included:

 

 

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation.  This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance.  The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

Use of our report

This report is made solely to the company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company’s members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

Julian Golding (Senior Statutory Auditor)
For and on behalf of Azets Audit Services, Statutory Auditor
Chartered Accountants
7 - 8 Britannia Business Park
Comet Way
Southend-On-Sea
Essex
SS2 6GE
24 September 2026
NORMEC LATIS SCIENTIFIC LIMITED
PROFIT AND LOSS ACCOUNT
FOR THE YEAR ENDED 31 DECEMBER 2025
- 8 -
2025
2024
Notes
£
£
Turnover
3
11,137,175
9,329,846
Cost of sales
(6,354,274)
(5,171,154)
Gross profit
4,782,901
4,158,692
Administrative expenses
(3,252,948)
(3,113,968)
Operating profit
4
1,529,953
1,044,724
Interest receivable and similar income
7
8,967
5,552
Interest payable and similar expenses
8
(45,197)
(79,142)
Profit before taxation
1,493,723
971,134
Tax on profit
9
(402,879)
(295,917)
Profit and total comprehensive income for the financial year
1,090,844
675,217
NORMEC LATIS SCIENTIFIC LIMITED
BALANCE SHEET
AS AT 31 DECEMBER 2025
31 December 2025
- 9 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
10
100,016
114,056
Tangible fixed assets
11
2,958,438
2,325,330
Deferred tax asset
17
53,519
94,491
3,111,973
2,533,877
Current assets
Stocks
12
172,000
190,338
Debtors
13
4,370,328
2,559,907
Cash at bank and in hand
324,391
342,555
4,866,719
3,092,800
Creditors: amounts falling due within one year
14
(2,682,794)
(2,075,971)
Net current assets
2,183,925
1,016,829
Total assets less current liabilities
5,295,898
3,550,706
Creditors: amounts falling due after more than one year
14
(1,178,358)
(524,010)
Provisions for liabilities
Other provisions
18
(661,257)
(661,257)
Net assets
3,456,283
2,365,439
Capital and reserves
Called up share capital
20
1,801,760
1,801,760
Share premium account
21
41,944
41,944
Capital redemption reserve
22
1,661
1,661
Profit and loss reserves
1,610,918
520,074
Total equity
3,456,283
2,365,439

These financial statements have been prepared in accordance with the provisions relating to medium-sized companies.

The financial statements were approved by the board of directors and authorised for issue on 24 September 2026 and are signed on its behalf by:
K Maynard
Director
Company registration number 01737587 (England and Wales)
NORMEC LATIS SCIENTIFIC LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2025
- 10 -
Share capital
Share premium account
Capital redemption reserve
Profit and loss reserves
Total
£
£
£
£
£
Balance at 1 January 2024
1,801,760
41,944
1,661
(155,143)
1,690,222
Year ended 31 December 2024:
Profit and total comprehensive income
-
-
-
675,217
675,217
Balance at 31 December 2024
1,801,760
41,944
1,661
520,074
2,365,439
Year ended 31 December 2025:
Profit and total comprehensive income
-
-
-
1,090,844
1,090,844
Balance at 31 December 2025
1,801,760
41,944
1,661
1,610,918
3,456,283
NORMEC LATIS SCIENTIFIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
- 11 -
1
Accounting policies
Company information

Normec Latis Scientific Limited is a private company limited by shares incorporated in England and Wales. The registered office is Unit C1 Acorn Industrial Park, Crayford Road, Crayford, Dartford, United Kingdom, DA1 4AL. The company's principal activities and nature of its operations are disclosed in the directors' report.

1.1
Accounting convention

The financial statements have been prepared in accordance with Financial Reporting Standard 101 Reduced Disclosure Framework (FRS 101) and in accordance with applicable accounting standards.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

As permitted by FRS 101, the company has taken advantage of the following disclosure exemptions from the requirements of IFRS:

- paragraph 79(a)(iv) of IAS 1;

- paragraph 73(e) of IAS 16 Property, Plant and Equipment;

- paragraph 118(e) of IAS 38 Intangible Assets;

 

Where required, equivalent disclosures are given in the group accounts of Greyhound Dutch Bidco B.V. as at 2025 and these financial statements are available to the public and can be obtained from Honthorststraat 3, 1071 DC Amsterdam, Netherlands.

1.2
Going concern

Having considered the Company’s funding position and financial projections (which include the cash position, net asset position and management's cash flow forecasts), the impact of the currenttrue cost of living crisis, the non-requirement to settle intercompany balances unless able to do so, and the availability of financial resources from the UK parent company, should it be required, the Directors have a reasonable expectation that the company will continue in operation and meet its liabilities as they fall due until 31 August 2027. For these reasons they continue to adopt the going concern basis in preparing the financial statements.

 

The directors have also received assurances from Greyhound Dutch Bidco B.V. they will provide financing as and when required for the going concern period through to 31 August 2027 if funds are required for the company to meet its liabilities as they fall due.

NORMEC LATIS SCIENTIFIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 12 -
1.3
Turnover

Revenue from contracts with customers

 

Revenue is recognised in accordance with IFRS 15 at an amount that reflects the consideration to which the Company is expected to be entitled in exchange for transferring goods or services to a customer. For each arrangement with a customer, the Company: identifies whether the arrangement meets the definition of a contract with a customer; identifies the performance obligations in the contract; determines the transaction price which takes into account estimates of variable consideration and the time value of money; allocates the transaction price to the separate performance obligations on the basis of the relative stand-alone selling price of each performance obligation to be delivered; and recognises revenue when or as each performance obligation is satisfied in a manner that depicts the transfer to the customer of the goods or services promised.

 

Variable consideration within the transaction price, if any, reflects concessions provided to the customer such as discounts or any other contingent events such as sales or usage-based royalties. Such estimates are determined using either the 'expected value' or 'most likely amount' method.

 

The measurement of variable consideration is subject to a constraining principle whereby revenue will only be recognised to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur. The measurement constraint continues until the uncertainty associated with the variable consideration is subsequently resolved. Amounts received that are subject to the constraining principle are initially recognised as deferred revenue in the form of a separate refund liability. Whenever applicable, the Company applies the variable consideration allocation exception to recognise revenue for variable amount related to a distinct service that forms part of a single performance obligation.

 

Consultancy services and Microbiology and chemistry services

Revenue from consultancy services and microbiology and chemistry services is the consideration the Company receives for providing consultancy services and water treatment testing to various customers. Transaction consideration consists of a fixed fee. Fixed fee revenue is recognised at a point in time, generally when the service is rendered.

 

Accrued income

Accrued income is the right to consideration in exchange for goods or services transferred to the customer. If the Company performs its obligations by transferring goods or services to a customer before the customer pays consideration or before payment is due, accrued income is recognised for the earned consideration.

 

Trade receivables

A receivable represents the Company’s right to an amount of consideration that is unconditional (i.e. only the passage of time is required before payment of the consideration is due). Refer to accounting policies of financial assets in section 2.16 Financial instruments. The Company’s trade receivables are all related to the value of revenue receivable from rendering services.

 

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

 

The company does not expect to have any contracts where the period between the transfer of the promised goods or services to the customer and payment by the customer exceeds one year. As a consequence, the company does not adjust any of the transaction prices for the time value of money.

 

Rendering of services

 

Revenue from providing services is recognised in the accounting period in which the services are rendered.

 

NORMEC LATIS SCIENTIFIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 13 -
1.4
Intangible assets other than goodwill

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

 

The estimated useful lives range as follows:

 

Computer software 3 - 8 years

1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Short-term leasehold land and buildings
10% straight line or over the life of the lease
Fixtures and fittings
10% straight line or over the life of the lease
Plant and equipment
12.5%-25% straight line
Computer equipment
25% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the profit and loss account.

1.6
Impairment of tangible and intangible assets

At each reporting end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Intangible assets with indefinite useful lives and intangible assets not yet available for use are tested for impairment annually, and whenever there is an indication that the asset may be impaired.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

 

Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

NORMEC LATIS SCIENTIFIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 14 -
1.7
Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

1.8
Cash at bank and in hand

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value

1.9
Financial assets

The Company is applying the requirements of IFRS 9 to all financial instruments.

 

The Company recognises financial instruments when it becomes a party to the contractual arrangements of the instrument. Financial instruments are de-recognised when they are discharged or when the contractual terms expire. The Company's accounting policies in respect of financial instruments transactions are explained below:

 

Financial assets and financial liabilities are initially measured at fair value.

 

Financial assets are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument. Financial assets are classified into specified categories, depending on the nature and purpose of the financial assets.

 

At initial recognition, financial assets classified as fair value through profit and loss are measured at fair value and any transaction costs are recognised in profit or loss. Financial assets not classified as fair value through profit and loss are initially measured at fair value plus transaction costs.

Financial assets at fair value through profit or loss

When any of the above-mentioned conditions for classification of financial assets is not met, a financial asset is classified as measured at fair value through profit or loss. Financial assets measured at fair value through profit or loss are recognized initially at fair value and any transaction costs are recognised in profit or loss when incurred. A gain or loss on a financial asset measured at fair value through profit or loss is recognised in profit or loss, and is included within finance income or finance costs in the statement of income for the reporting period in which it arises.

Financial assets held at amortised cost

Financial instruments are classified as financial assets measured at amortised cost where the objective is to hold these assets in order to collect contractual cash flows, and the contractual cash flows are solely payments of principal and interest. They arise principally from the provision of goods and services to customers (eg trade receivables). They are initially recognised at fair value plus transaction costs directly attributable to their acquisition or issue, and are subsequently carried at amortised cost using the effective interest rate method, less provision for impairment where necessary.

NORMEC LATIS SCIENTIFIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 15 -
Financial assets at fair value through other comprehensive income

Debt instruments are classified as financial assets measured at fair value through other comprehensive income where the financial assets are held within the company’s business model whose objective is achieved by both collecting contractual cash flows and selling financial assets, and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

 

A debt instrument measured at fair value through other comprehensive income is recognised initially at fair value plus transaction costs directly attributable to the asset. After initial recognition, each asset is measured at fair value, with changes in fair value included in other comprehensive income. Accumulated gains or losses recognised through other comprehensive income are directly transferred to profit or loss when the debt instrument is derecognised.

The company has made an irrevocable election to recognize changes in fair value of investments in equity instruments through other comprehensive income, not through profit or loss. A gain or loss from fair value changes will be shown in other comprehensive income and will not be reclassified subsequently to profit or loss. Equity instruments measured at fair value through other comprehensive income are recognized initially at fair value plus transaction cost directly attributable to the asset. After initial recognition, each asset is measured at fair value, with changes in fair value included in other comprehensive income. Accumulated gains or losses recognized through other comprehensive income are directly transferred to retained earnings when the equity instrument is derecognized or its fair value substantially decreased. Dividends are recognized as finance income in profit or loss.

Impairment of financial assets

For trade receivables that are expected to have a maturity of one year or less, the Company has applied the practical expedient and followed the simplified approach in calculating ECLs. Therefore, the Company does not track changes in credit risk, but instead recognises a loss allowance based on lifetime ECLs at each reporting date. The Company has established a provision matrix that is based on its historical credit loss experience, adjusted for forward looking factors specific to the debtors and the economic environment.

 

For trade receivables expected credit losses are measured by applying an expected loss rate to the gross carrying amount. The expected loss rate comprises the risk of a default occurring and the expected cash flows on default based on the aging of the receivable. The risk of a default occurring always takes into consideration all possible default events over the expected life of those receivables ('the lifetime expected credit losses'). Different provision rates and periods are used based on groupings of historic credit loss experience by product type, customer type and location.

 

The Company considers a financial asset in default when contractual payments are 90 days past due. However, in certain cases, the Company may also consider a financial asset to be in default when internal or external information indicates that the Company is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the Company.

 

A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.

Derecognition of financial assets

A financial asset is primarily derecognised when:

• The rights to receive cash flows from the asset have expired, or;

• The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a ‘pass through’ arrangement and either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

NORMEC LATIS SCIENTIFIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 16 -
1.10
Financial liabilities

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, as appropriate.

 

All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings, net of directly attributable transaction costs.

 

The company’s financial liabilities include trade and other payables and amounts owed to group undertakings.

1.11
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of direct issue costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.12
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax is the tax expected to be payable or recoverable on differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit, and is accounted for using the balance sheet liability method. Deferred tax liabilities are generally recognised for all taxable temporary differences and deferred tax assets are recognised to the extent that it is probable that taxable profits will be available against which deductible temporary differences can be utilised. Such assets and liabilities are not recognised if the temporary difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

NORMEC LATIS SCIENTIFIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 17 -
1.13
Provisions

Provisions are recognised when the company has a legal or constructive present obligation as a result of a past event and it is probable that the company will be required to settle that obligation, and a reliable estimate can be made of the amount of the obligation.

 

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting end date, taking into account the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows.

 

When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, a receivable is recognised as an asset if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

1.14
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of inventories or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.15
Retirement benefits

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

 

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance sheet. The assets of the plan are held separately from the Company in independently administered funds.

1.16
Leases
As lessee

At inception, the company assesses whether a contract is, or contains, a lease within the scope of IFRS 16. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Where a tangible asset is acquired through a lease, the company recognises a right-of-use asset and a lease liability at the lease commencement date. Right-of-use assets are included within tangible fixed assets, apart from those that meet the definition of investment property.

The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the commencement date plus any initial direct costs and an estimate of the cost of obligations to dismantle, remove, refurbish or restore the underlying asset and the site on which it is located, less any lease incentives received.

 

The right-of-use asset is subsequently adjusted for remeasurements of the lease liability and applies the relevant cost model, fair value model or revaluation model as set out within the accounting policies for the applicable asset class. Where the cost model is applied, the asset is depreciated from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term, and is periodically reduced by impairment losses, if any.

NORMEC LATIS SCIENTIFIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 18 -

The lease liability is initially measured at the present value of the lease payments that are unpaid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the company's incremental borrowing rate. Lease payments included in the measurement of the lease liability comprise fixed payments, variable lease payments that depend on an index or a rate, amounts expected to be payable under a residual value guarantee, and the cost of any options that the company is reasonably certain to exercise, such as the exercise price under a purchase option, lease payments in an optional renewal period, or penalties for early termination of a lease.

The lease liability is measured at amortised cost using the effective interest method. It is reassessed at each financial period end to reflect lease modifications and any changes to the factors considered at initial measurement, as set out above. When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset, or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.

The company has elected not to recognise right-of-use assets and lease liabilities for short-term leases of machinery that have a lease term of 12 months or less, or for leases of low-value assets including IT equipment. The payments associated with these leases are recognised in profit or loss on a straight-line basis over the lease term.

1.17

Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

1.18

Creditors

Creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers.

Creditors are recognised initially at fair value and subsequently measured at amortised cost using the effective interest method.

2
Critical accounting estimates and judgements

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

 

The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are outlined below.

Critical judgements
Dilapidations

A third party valuation has been carried out to determine the value of the dilapidations provision for the Crayford facility to return the building to its original condition. This is estimated at £661k (2024: £661k).

IFRS 9 Financial Instruments

Management has based its IFRS 9 expected credit loss (ECL) calculation on a combination of historic debt collection rates and the mix of debt between different sectors.

NORMEC LATIS SCIENTIFIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
2
Critical accounting estimates and judgements
(Continued)
- 19 -
Deferred Tax

Management judgment is required to determine the amount of deferred tax assets that can be recognised, based on the likely timing and level of future profits.

Fixed Assets

Management judgment is required to determine the useful economic life of fixed assets, as well as annual consideration of recoverable value against net book value. The company's policy for impairment of intangible and tangible fixed assets is disclosed in note 1.6.

In preparing these financial statements, the directors have had to make the following judgments:

• Determine whether there are indicators of impairment of the company's tangible and intangible assets. Factors taken into consideration in reaching such a decision include the economic viability and expected future financial performance of the asset.

Key sources of estimation uncertainty
Tangible fixed assets

Tangible fixed assets are depreciated over their useful lives taking into account residual values, where appropriate. The actual lives of the assets and residual values are assessed annually and may vary depending on the number of factors. In re-assessing asset lives, factors such as technological innovation, product life cycles and maintenance programmes are taken into account. Residual value assessments consider issues such as future market conditions, the remaining life of the asset and projected disposal values.

3
Turnover
2025
2024
£
£
Turnover analysed by class of business
Sales of microbiology, chemistry and consultancy services
11,137,175
9,329,846
2025
2024
£
£
Turnover analysed by geographical market
United Kingdom
11,137,175
9,329,846
4
Operating profit
2025
2024
Operating profit for the year is stated after charging/(crediting):
£
£
Exchange losses
8,914
-
Fees payable to the company's auditor for the audit of the company's financial statements
32,500
57,426
Depreciation of property, plant and equipment
377,974
403,310
Amortisation of intangible assets (included within administrative expenses)
29,577
20,182
Cost of inventories recognised as an expense
2,148,012
1,702,626
NORMEC LATIS SCIENTIFIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 20 -
5
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Sales
5
5
Administration
17
17
Operational
83
78
Total
105
100

Their aggregate remuneration comprised:

2025
2024
£
£
Wages and salaries
3,786,787
3,086,054
Social security costs
367,998
243,636
Pension costs
109,635
191,895
4,264,420
3,521,585
6
Directors' remuneration
2025
2024
£
£
Remuneration for qualifying services
35,323
51,069
Company pension contributions to defined contribution schemes
5,282
1,988
40,605
53,057

Some directors of the company during the year received no remuneration from the company. The directors of the company are also directors of other UK and non UK group companies and their total remuneration is paid by other group companies. The directors estimate the allocated remuneration for their qualifying services to the company as 1 director at 50% of their time as a serving director (2024 - 50%) of their time which equates to a value of £35,323 (2024 - £51,069), with the same % distribution per director for the defined contribution scheme to the value of £5,282 (2024 - £1,988).

 

None of the company's directors received any shares in any group company during the year in respect of qualifying services, nor exercised any share options over shares in the parent company.

7
Interest receivable and similar income
2025
2024
£
£
Interest income
Interest receivable from group companies
8,967
5,552
NORMEC LATIS SCIENTIFIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 21 -
8
Interest payable and similar expenses
2025
2024
£
£
Interest on financial liabilities measured at amortised cost:
Interest payable to group undertakings
6,229
37,160
Interest on lease liabilities
38,968
41,982
45,197
79,142
9
Taxation
2025
2024
£
£
Current tax
UK corporation tax on profits for the current period
394,114
274,477
Adjustments in respect of prior periods
(32,207)
11,305
Total UK current tax
361,907
285,782
Deferred tax
Origination and reversal of temporary differences
14,492
10,135
Adjustment in respect of prior periods
26,480
-
0
40,972
10,135
Total tax charge
402,879
295,917

The charge for the year can be reconciled to the profit per the profit and loss account as follows:

2025
2024
£
£
Profit before taxation
1,493,723
971,134
Expected tax charge based on a corporation tax rate of 25.00% (2024: 25.00%)
373,431
242,784
Effect of expenses not deductible in determining taxable profit
343
182
Income not taxable
-
0
(25)
Adjustment in respect of prior years
(32,207)
11,305
Deferred tax adjustments in respect of prior years
26,480
-
Fixed asset differences
34,832
41,671
Taxation charge for the year
402,879
295,917
NORMEC LATIS SCIENTIFIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 22 -
10
Intangible fixed assets
Software
£
Cost
At 31 December 2024
250,612
Additions - internally generated
15,537
At 31 December 2025
266,149
Amortisation and impairment
At 31 December 2024
136,556
Charge for the year
29,577
At 31 December 2025
166,133
Carrying amount
At 31 December 2025
100,016
At 31 December 2024
114,056
11
Tangible fixed assets
Short-term leasehold land and buildings
Plant and equipment
Fixtures and fittings
Computer equipment
Motor vehicles
Total
£
£
£
£
£
£
Cost
At 1 January 2025
4,808,142
1,230,484
48,360
109,664
-
0
6,196,650
Additions
1,408,631
160,435
-
0
4,242
-
0
1,573,308
Disposals
(1,151,688)
-
0
-
0
-
0
-
0
(1,151,688)
At 31 December 2025
5,065,085
1,390,919
48,360
113,906
-
0
6,618,270
Accumulated depreciation and impairment
At 1 January 2025
2,906,796
842,406
40,661
81,457
-
0
3,871,320
Charge for the year
228,592
134,327
3,979
11,076
-
0
377,974
Eliminated on disposal
(589,462)
-
0
-
0
-
0
-
0
(589,462)
At 31 December 2025
2,545,926
976,733
44,640
92,533
-
0
3,659,832
Carrying amount
At 31 December 2025
2,519,159
414,186
3,720
21,373
-
0
2,958,438
At 31 December 2024
1,901,346
388,078
7,699
28,207
-
0
2,325,330
NORMEC LATIS SCIENTIFIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
11
Tangible fixed assets
(Continued)
- 23 -

Tangible fixed assets includes right-of-use assets, as follows:

Right-of-use assets
2025
2024
£
£
Net values at the year end
Property
1,335,850
599,067
Depreciation charge for the year
Property
89,264
85,197
The carrying value of land and buildings comprises:
2025
2024
£
£
Short leasehold
2,519,159
1,901,346
12
Stocks
2025
2024
£
£
Raw materials
172,000
190,338
13
Debtors
2025
2024
£
£
Trade debtors
2,355,098
2,183,040
Amounts owed by fellow group undertakings
1,465,416
-
0
Other debtors
110,108
3,572
Prepayments and accrued income
439,706
373,295
4,370,328
2,559,907
14
Creditors
Due within one year
Due after one year
2025
2024
2025
2024
Notes
£
£
£
£
Creditors
15
1,985,669
1,805,332
-
0
-
0
Corporation tax
186,084
-
0
-
-
Other taxation and social security
330,039
164,928
-
-
Lease liabilities
16
181,002
105,711
1,178,358
524,010
2,682,794
2,075,971
1,178,358
524,010
NORMEC LATIS SCIENTIFIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 24 -
15
Creditors
2025
2024
£
£
Trade creditors
433,877
228,594
Amounts owed to fellow group undertakings
1,264,733
1,150,952
Accruals and deferred income
287,059
312,590
Other creditors
-
113,196
1,985,669
1,805,332

At acquisition a new loan facility of £5 million was provided by Normec Environmental Testing Services Limited and at 31 December 2025 a drawdown of £1,115,397 (2024: £830,084) was made. This loan is repayable on demand and bears interest at a rate of 3% per annum.

16
Lease liabilities
2025
2024
Maturity analysis of lease payments
£
£
Within one year
181,002
105,711
In two to five years
724,008
123,226
In over five years
454,350
400,784
Total undiscounted liabilities
1,359,360
629,721

Lease liabilities are classified based on the amounts that are expected to be settled within the next 12 months and after more than 12 months from the reporting date, as follows:

2025
2024
£
£
Current liabilities
181,002
105,711
Non-current liabilities
1,178,358
524,010
1,359,360
629,721
17
Deferred taxation
Assets
2025
2024
£
£
Deferred tax balances
53,519
94,491
Deferred tax assets are expected to be recovered within one year.
NORMEC LATIS SCIENTIFIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
17
Deferred taxation
(Continued)
- 25 -

The following are the major deferred tax liabilities and assets recognised by the company and movements thereon during the current and prior reporting period.

ACAs
Short term temporary differences
Total
£
£
£
Asset at 1 January 2024
(59,721)
164,347
104,626
Deferred tax movements in prior year
Credit/(charge) to profit or loss
-
(10,135)
(10,135)
Asset at 1 January 2025
(59,721)
154,212
94,491
Deferred tax movements in current year
Credit/(charge) to profit or loss
(52,074)
11,102
(40,972)
Asset at 31 December 2025
(111,795)
165,314
53,519
18
Provisions for liabilities
2025
2024
£
£
Dilapidation
661,257
661,257
Movements on provisions:
Dilapidation
£
At 1 January 2025 and 31 December 2025
661,257

Other provisions include the following items:

 

£661,257 (2024: £661,257) for dilapidation of Crayford, which has to be restored to its original state upon exit in August 2035 as per the lease extension. Third party valuations have been carried out to obtain values for the dilapidation provisions.

 

19
Retirement benefit schemes
2025
2024
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
109,635
191,895

The company operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the company in an independently administered fund.

NORMEC LATIS SCIENTIFIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 26 -
20
Share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary B shares of 1p each
180,176,013
180,176,013
1,801,760
1,801,760
21
Share premium account
2025
2024
£
£
At the beginning and end of the year
41,944
41,944
22
Capital redemption reserve
2025
2024
£
£
At the beginning and end of the year
1,661
1,661
23
Controlling party

Greyhound Dutch Bidco B.V. is the ultimate parent company.

 

Normec Environmental Testing Services Limited is the immediate parent company.

 

The parent undertaking of the smallest group (Normec 1 B.V.) and the largest group (Greyound Dutch Bidco B.V.) which includes the company and for which group accounts are prepared is Greyound Dutch Bidco B.V.. Copies of the group financial statements are available from Honthorststraat 3, 1071 DC Amsterdam, Netherlands.

2025-12-312025-01-01Ms B D SchuursMs M H van SchaikMr R M WolffK BridgewoodK MaynardfalsefalseCCH SoftwareiXBRL Review & Tag 2025.2017375872025-01-012025-12-3101737587bus:Director12025-01-012025-12-3101737587bus:Director22025-01-012025-12-3101737587bus:Director52025-01-012025-12-3101737587bus:Director32025-01-012025-12-3101737587bus:Director42025-01-012025-12-3101737587bus:RegisteredOffice2025-01-012025-12-31017375872025-12-31017375872024-01-012024-12-3101737587core:RetainedEarningsAccumulatedLosses2025-01-012025-12-3101737587core:RetainedEarningsAccumulatedLosses2024-01-012024-12-3101737587core:IntangibleAssetsOtherThanGoodwill2025-12-3101737587core:IntangibleAssetsOtherThanGoodwill2024-12-3101737587core:ComputerSoftware2025-12-3101737587core:ComputerSoftware2024-12-31017375872024-12-3101737587core:LandBuildingscore:LeasedAssetsHeldAsLessee2025-12-3101737587core:PlantMachinery2025-12-3101737587core:FurnitureFittings2025-12-3101737587core:ComputerEquipment2025-12-3101737587core:MotorVehicles2025-12-3101737587core:ContinuingOperations2025-12-3101737587core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-12-3101737587core:PlantMachinery2024-12-3101737587core:FurnitureFittings2024-12-3101737587core:ComputerEquipment2024-12-3101737587core:MotorVehicles2024-12-3101737587core:AcceleratedTaxDepreciationDeferredTax2023-12-3101737587core:AcceleratedTaxDepreciationDeferredTax2024-12-3101737587core:AcceleratedTaxDepreciationDeferredTax2025-12-3101737587core:BetweenOneFiveYears2024-12-3101737587core:CurrentFinancialInstruments2025-12-3101737587core:CurrentFinancialInstruments2024-12-3101737587core:Non-currentFinancialInstruments2025-12-3101737587core:Non-currentFinancialInstruments2024-12-3101737587core:ShareCapital2025-12-3101737587core:ShareCapital2024-12-3101737587core:SharePremium2025-12-3101737587core:SharePremium2024-12-3101737587core:CapitalRedemptionReserve2025-12-3101737587core:CapitalRedemptionReserve2024-12-3101737587core:RetainedEarningsAccumulatedLosses2025-12-3101737587core:RetainedEarningsAccumulatedLosses2024-12-31017375872023-12-3101737587core:UKTax2025-01-012025-12-3101737587core:UKTax2024-01-012024-12-3101737587core:ComputerSoftware2025-01-012025-12-3101737587core:ComputerSoftware2024-12-3101737587core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-12-3101737587core:PlantMachinery2024-12-3101737587core:FurnitureFittings2024-12-3101737587core:ComputerEquipment2024-12-3101737587core:MotorVehicles2024-12-31017375872024-12-3101737587core:LandBuildingscore:LeasedAssetsHeldAsLessee2025-01-012025-12-3101737587core:PlantMachinery2025-01-012025-12-3101737587core:FurnitureFittings2025-01-012025-12-3101737587core:ComputerEquipment2025-01-012025-12-3101737587core:MotorVehicles2025-01-012025-12-3101737587core:LandBuildingscore:ShortLeaseholdAssets2025-12-3101737587core:LandBuildingscore:ShortLeaseholdAssets2024-12-3101737587core:CurrentFinancialInstrumentscore:WithinOneYear2025-12-3101737587core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3101737587core:Non-currentFinancialInstrumentscore:AfterOneYear2025-12-3101737587core:Non-currentFinancialInstrumentscore:AfterOneYear2024-12-3101737587bus:PrivateLimitedCompanyLtd2025-01-012025-12-3101737587bus:FRS1012025-01-012025-12-3101737587bus:Audited2025-01-012025-12-3101737587bus:FullAccounts2025-01-012025-12-31xbrli:purexbrli:sharesiso4217:GBP